Related Experiment Video
Updated: May 17, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Blood alterations preceding clinical manifestation of glioblastoma
Aysegül Ilhan-Mutlu1, Ludwig Wagner, Adelheid Wöhrer
1Department of Oncology, Medical University of Vienna, Vienna, Austria.
Background:
There is little knowledge on blood alterations of glioblastoma. We had the opportunity to investigate markers from plasma taken 66, 36, and 6 months before glioblastoma in a patient in the VITA study.
Methods:
We determined S100B, secretagogin, neuropeptide-Y, micro-RNA-21, let-7, micro-RNA-128, and micro-RNA-342-3p in our patient and 10 controls from VITA.
Results:
We found a four-fold increase of micro-RNA-21 in the plasma of glioblastoma patient, whereas controls showed a significant decrease. There was no difference in other protein or micro-RNA levels between the patient and controls.
Conclusion:
Plasma micro-RNA-21 may be associated with glioblastoma development in individual cases.
Related Concept Videos
Hemorrhagic Stroke ll: Pathophysiology
Hemorrhagic Stroke l: Introduction

